Rankings
▼
Calendar
JANX
Janux Therapeutics, Inc.
$835M
FY 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$6,000
Operating Income
-$4M
Net Income
-$4M
EPS (Diluted)
$-0.10
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$4M
Stock-Based Comp.
$6,000
Balance Sheet
Total Assets
$679,000
Total Liabilities
$9M
Stockholders' Equity
-$8M
Cash & Equivalents
$658,000
← Q1 2020
All Quarters
JANX FY 2019 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
